Current research in empirical therapy for febrile neutropenia in cancer patients: what should be necessary and what is going on

Bibliography

• Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966;64:328-40
   PubMed Web of Science ®Google Scholar
• DuPont HL, Spink WW. Infections due to gram-negatives organisms: an analysis of 860 patients with bacteremia at the University of Minnesota Medical Center, 1958-1966. Medicine (Baltimore) 1969;48:307-32
   PubMed Web of Science ®Google Scholar
• Viscoli C; Group obotEIAT. Management of infection in cancer patients: studies of the EORTC International Antimicrobial Therapy Group (IATG). Eur J Cancer 2002;38:S82-7
   PubMed Web of Science ®Google Scholar
• Klastersky J, Ameye L, Maertens J, et al. Bacteraemia in febrile neutropenic cancer patients. Int J Antimicrob Agents 2007;30S:S51-9
   Google Scholar
• Caselli D, Cesaro S, Ziino O, et al. Multidrug resistant Pseudomonas aeruginosa infection in children undergoing chemotherapy and hematopoietic stem cell transplantation. Haematologica 2010;95:1612-15
   PubMed Web of Science ®Google Scholar
• Cattaneo C, Casari S, Bracchi F, et al. Recent increase in enterococci, viridans streptococci, Pseudomonas spp. and multiresistant strains among haematological patients, with a negative impact on outcome. Results of a 3-year surveillance study at a single institution. Scand J Infect Dis 2010;42:324-32
   PubMed Web of Science ®Google Scholar
• Kang CI, Chung DR, Ko KS, et al. Risk factors for infection and treatment outcome of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae bacteremia in patients with hematologic malignancy. Ann Hematol 2012;91:115-21
   PubMed Web of Science ®Google Scholar
• Kang CI, Song JH, Ko KS, et al. Clinical features and outcomes of Staphylococcus aureus infections in non-neutropenic cancer patients. Support Care Cancer 2012;20:483-8
   PubMed Web of Science ®Google Scholar
• Trecarichi EM, Tumbarello M, Caira M, et al. Multidrug resistant Pseudomonas aeruginosa bloodstream infection in adult patients with hematologic malignancies. Haematologica 2011;96:e1-3; author reply e4
   PubMed Web of Science ®Google Scholar
• Kang CI, Kim SH, Park WB, et al. Bloodstream infections caused by antibiotic-resistant gram-negative bacilli: risk factors for mortality and impact of inappropriate initial antimicrobial therapy on outcome. Antimicrob Agents Chemother 2005;49:760-6
   PubMed Web of Science ®Google Scholar
• Horasan ES, Ersoz G, Horoz M, et al. Risk factors for infections caused by multidrug-resistant bacteria in patients with solid tumours. Scand J Infect Dis 2011;43:107-11
   PubMed Web of Science ®Google Scholar
• El-Mahallawy HA, El-Wakil M, Moneer MM, Shalaby L. Antibiotic resistance is associated with longer bacteremic episodes and worse outcome in febrile neutropenic children with cancer. Pediatr Blood Cancer 2011;57:283-8
   PubMed Web of Science ®Google Scholar
• Freifeld AG, Sepkowitz KA. No place like home? Outpatient management of patients with febrile neutropenia and low risk. J Clin Oncol 2011;29:3952-4
   PubMed Web of Science ®Google Scholar
• Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2011;52:e56-93
   PubMed Web of Science ®Google Scholar
• Lehrnbecher T, Phillips R, Alexander S, et al. Guideline for the management of fever and neutropenia in children with cancer and/or undergoing hematopoietic stem-cell transplantation. J Clin Oncol 2012;30:4427-38
   PubMed Web of Science ®Google Scholar
• de Pauw BE, Donnelly JP. Timely intervention for invasive fungal disease: should the road now lead to the laboratory instead of the pharmacy? Clin Infect Dis 2009;48:1052-4
   PubMed Web of Science ®Google Scholar
• Elliott TR. Registering randomized clinical trials and the case for CONSORT. Exp Clin Psychopharmacol 2007;15:511-18
   PubMed Web of Science ®Google Scholar
• DeAngelis CD, Drazen JM, Frizelle FA, et al. Clinical trial registration: a statement from the International Committee of Medical Journal Editors. JAMA 2004;292:1363-4
   PubMed Web of Science ®Google Scholar
• Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. Ann Intern Med 2010;152:726-32
   PubMed Web of Science ®Google Scholar
• Available from: http://www.clinicaltrials.gov [Accessed 14 February 2013]
   Google Scholar
• Available from: http://apps.who.int/trialsearch/default.aspx [Accessed 14 February 2013]
   Google Scholar
• Available from: http://www.controlled-trials.com/ [Accessed 14 February 2013]
   Google Scholar
• Available from: http://www.clinicaltrialsregister.eu [Accessed 14 February 2013]
   Google Scholar
• Available from: http://www.umin.ac.jp/ctr/ [Accessed 14 February 2013]
   Google Scholar
• Klastersky J, Paesmans M, Rubenstein EB, et al. The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 2000;18:3038-51
   PubMed Web of Science ®Google Scholar
• Macher E, Dubos F, Garnier N, et al. Predicting the risk of severe bacterial infection in children with chemotherapy-induced febrile neutropenia. Pediatr Blood Cancer 2010;55:662-7
   PubMed Web of Science ®Google Scholar
• Phillips B, Wade R, Stewart LA, Sutton AJ. Systematic review and meta-analysis of the discriminatory performance of risk prediction rules in febrile neutropaenic episodes in children and young people. Eur J Cancer 2010;46:2950-64
   PubMed Web of Science ®Google Scholar
• Phillips RS, Lehrnbecher T, Alexander S, Sung L. Updated systematic review and meta-analysis of the performance of risk prediction rules in children and young people with febrile neutropenia. PLoS One 2012;7:e38300
   PubMed Web of Science ®Google Scholar
• Torfoss D, Hoiby EA, Tangen JM, et al. Tobramycin once versus three times daily, given with penicillin G, to febrile neutropenic cancer patients in Norway: a prospective, randomized, multicentre trial. J Antimicrob Chemother 2007;59:711-17
   PubMed Web of Science ®Google Scholar
• Jaksic B, Martinelli G, Perez-Oteyza J, et al. Efficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer. Clin Infect Dis 2006;42:597-607
   PubMed Web of Science ®Google Scholar
• Bow EJ, Rotstein C, Noskin GA, et al. A randomized, open-label, multicenter comparative study of the efficacy and safety of piperacillin-tazobactam and cefepime for the empirical treatment of febrile neutropenic episodes in patients with hematologic malignancies. Clin Infect Dis 2006;43:447-59
   PubMed Web of Science ®Google Scholar
• Finch RG, Greenwood D, Norrby SR, Whitley RJ. Antibiotic and chemotherapy. Anti-infective agents and their use in therapy. Elsevier, Ltd; London: 2010
   Google Scholar
• European Committee for Antimicrobial Susceptibility Testing E. Breakpoint tables for interpretation of MICs and zone diameters. Version 3.0, valid from 2013-01-01. 2013. Available from: http://http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Disk_test_documents/EUCAST_Breakpoint_table_v_3.0.pdf
   Google Scholar
• Reese AM, Frei CR, Burgess DS. Pharmacodynamics of intermittent and continuous infusion piperacillin/tazobactam and cefepime against extended-spectrum beta-lactamase-producing organisms. Int J Antimicrob Agents 2005;26:114-19
   PubMed Web of Science ®Google Scholar
• Rossolini GM, Dryden MS, Kozlov RS, et al. Comparative activity of ceftobiprole against Gram-positive and Gram-negative isolates from Europe and the Middle East: the CLASS study. J Antimicrob Chemother 2011;66:151-9
   PubMed Web of Science ®Google Scholar
• Walkty A, Adam HJ, Laverdiere M, et al. In vitro activity of ceftobiprole against frequently encountered aerobic and facultative Gram-positive and Gram-negative bacterial pathogens: results of the CANWARD 2007-2009 study. Diagn Microbiol Infect Dis 2011;69:348-55
   PubMed Web of Science ®Google Scholar
• Nakao M, Noji Y, Iwahi T, Yamazaki T. Antibacterial properties of SCE-2787, a new cephem antibiotic. J Antimicrob Chemother 1992;29:509-18
   PubMed Web of Science ®Google Scholar
• Rybak MJ, Lomaestro BM, Rotschafer JC, et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis 2009;49:325-7
   PubMed Web of Science ®Google Scholar
• Leibovici L, Yahav D, Paul M. Meta-analysis of a possible signal of increased mortality associated with cefepime use. Clin Infect Dis 2010;51:1350-1; author reply 51-2
   PubMed Web of Science ®Google Scholar
• Leibovici L, Yahav D, Paul M. Excess mortality related to cefepime. Lancet Infect Dis 2010;10:293-4
   PubMed Web of Science ®Google Scholar
• Chopra T, Marchaim D, Veltman J, et al. Impact of cefepime therapy on mortality among patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli. Antimicrob Agents Chemother 2012;56:3936-42
   PubMed Web of Science ®Google Scholar
• Adembri C, Novelli A. Pharmacokinetic and pharmacodynamic parameters of antimicrobials: potential for providing dosing regimens that are less vulnerable to resistance. Clin Pharmacokinet 2009;48:517-28
   PubMed Web of Science ®Google Scholar
• Chaudhary M, Shrivastava SM, Varughese L, Sehgal R. Efficacy and safety evaluation of fixed dose combination of cefepime and amikacin in comparison with cefepime alone in treatment of nosocomial pneumonia patients. Curr Clin Pharmacol 2008;3:118-22
   PubMedGoogle Scholar
• Anonymous. Efficacy and toxicity of single daily doses of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Ann Intern Med 1993;119:584-93
   PubMedGoogle Scholar
• Kobayashi S, Ito M, Sano H, et al. Clinical analysis of combination therapy for febrile neutropenic patients in childhood cancer. Pediatr Int 2013;55:65-71
   PubMed Web of Science ®Google Scholar
• Ichikawa M, Suzuki D, Ohshima J, et al. Piperacillin/tazobactam versus cefozopran for the empirical treatment of pediatric cancer patients with febrile neutropenia. Pediatr Blood Cancer 2011;57:1159-62
   PubMed Web of Science ®Google Scholar
• Sato T, Kobayashi R, Yasuda K, et al. A prospective, randomized study comparing cefozopran with piperacillin-tazobactam plus ceftazidime as empirical therapy for febrile neutropenia in children with hematological disorders. Pediatr Blood Cancer 2008;51:774-7
   PubMed Web of Science ®Google Scholar
• Bucaneve G, Micozzi A, Program GI. Multicenter, randomized clinical trial comparing monotherapy with piperacillin-tazobactam versus piperacillin-tazobactam plus tigecycline as empiric therapy for febrile neutropenic cancer patients. Interscience Conference on Antimicrobial Agents and Chemotherapy; American Society for Microbiology, San Francisco2011
   Google Scholar
• Cai Y, Wang R, Liang B, et al. Systematic review and meta-analysis of the effectiveness and safety of tigecycline for treatment of Infectious disease. Antimicrob Agents Chemother 2011;55:1162-72
   PubMed Web of Science ®Google Scholar
• Yahav D, Lador A, Paul M, Leibovici L. Efficacy and safety of tigecycline: a systematic review and meta-analysis. J Antimicrob Chemother 2011;66:1936-71
   PubMedGoogle Scholar
• Bhavnani SM, Rubino CM, Hammel JP, et al. Pharmacological and patient-specific response determinants in patients with hospital-acquired pneumonia treated with tigecycline. Antimicrob Agents Chemother 2012;56:1065-72
   PubMed Web of Science ®Google Scholar
• Ramirez J, Dartois N, Gandjini H, et al. A randomized phase 2 trial to evaluate the clinical efficacy of two high tigecycline dosage regimens versus imipenem/cilastatin in hospital-acquired pneumonia. Antimicrob Agents Chemother 2013; Epub ahead of print
   Web of Science ®Google Scholar
• Mikulska M, Del Bono V, Prinapori R, et al. Risk factors for enterococcal bacteremia in allogeneic hematopoietic stem cell transplant recipients. Transpl Infect Dis 2010;12:505-12
   PubMed Web of Science ®Google Scholar
• Cometta A, Kern WV, De Bock R, et al. Vancomycin versus placebo for treating persistent fever in patients with neutropenic cancer receiving piperacillin-tazobactam monotherapy. Clin Infect Dis 2003;37:382-9
   PubMed Web of Science ®Google Scholar
• Pertel PE, Eisenstein BI, Link AS, et al. The efficacy and safety of daptomycin vs. vancomycin for the treatment of cellulitis and erysipelas. Int J Clin Pract 2009;63:368-75
   PubMed Web of Science ®Google Scholar
• Fowler VGJ, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006;355:653-335
   PubMed Web of Science ®Google Scholar
• Rehm SJ, Boucher H, Levine D, et al. Captomycin versus vancomycin plus gentamicin for treatment of bacteraemia and endocarditis die to Staphylococcus aureus: subset analysis of patients infected with methicillin-resistant isolates. J Antimicrob Chemother 2008;62:1413-21
   PubMed Web of Science ®Google Scholar
• Kullar R, Davis SL, Levine DP, et al. High-dose daptomycin for treatment of complicated Gram-positive infections: a large, multicenter, retrospective study. Pharmacotherapy 2011;31:627-536
   Google Scholar
• Katz DE, Lindfield KC, Steenbergen JN, et al. A pilot study of high-dose short duration daptomycin for the treatment of patients with complicated skin and skin structure infections caused by Gram-positive bacteria. Int J Clin Pract 2008;62:1455-64
   PubMed Web of Science ®Google Scholar
• Moise PA, Hershberger E, Amodio-Groton MI, Lamp KC. Safety and clinical outcomes when utilizing high-dose (> or =8 mg/kg) daptomycin therapy. Ann Pharmacother 2009;43:1211-19
   PubMed Web of Science ®Google Scholar
• Chakraborty A, Roy S, Loeffler J, Chaves RL. Comparison of the pharmacokinetics, safety and tolerability of daptomycin in healthy adult volunteers following intravenous administration by 30 min infusion or 2 min injection. J Antimicrob Chemother 2009;64:151-8
   PubMed Web of Science ®Google Scholar
• Bush K. Improving known classes of antibiotics: an optimistic approach for the future. Curr Opin Pharmacol 2012;12:527-34
   PubMed Web of Science ®Google Scholar
• Bazan JA, MArtin SI, Kaye KM. Newer beta-lactam antibiotics: doripenem, ceftobiprole, ceftaroline, and cefepime. Med Clin North Am 2011;95:743-60
   PubMed Web of Science ®Google Scholar
• Sader HS, Rhomberg PR, Farrell DJ, Jones RN. Antimicrobial activity of CXA-101, a novel cephalosporin tested in combination with tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis strains having various resistance phenotypes. Antimicrob Agents Chemother 2011;55:2390-4
   PubMed Web of Science ®Google Scholar
• Moya B, Zamorano L, Juan C, et al. Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients. Antimicrob Agents Chemother 2010;54:1213-17
   PubMed Web of Science ®Google Scholar
• Bulik CC, Tessier PR, Keel RA, et al. In vivo comparison of CXA-101 (FR264205) with and without tazobactam versus piperacillin-tazobactam using human simulated exposures against phenotypically diverse gram-negative organisms. Antimicrob Agents Chemother 2012;56:544-9
   PubMed Web of Science ®Google Scholar
• Juan C, Zamorano L, Perez JL, et al. Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains. Antimicrob Agents Chemother 2010;54:846-51
   PubMed Web of Science ®Google Scholar
• Mushtaq S, Warner M, Ge Y, et al. In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes. J Antimicrob Chemother 2007;60:300-11
   PubMed Web of Science ®Google Scholar
• Vidaillac C, Leonard SN, Sader HS, et al. In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrob Agents Chemother 2009;53:2360-6
   PubMed Web of Science ®Google Scholar
• Page MG, Dantier C, Desarbre E, et al. In vitro and in vivo properties of BAL30376, a beta-lactam and dual beta-lactamase inhibitor combination with enhanced activity against Gram-negative Bacilli that express multiple beta-lactamases. Antimicrob Agents Chemother 2011;55:1510-19
   PubMed Web of Science ®Google Scholar
• Livermore DM, Mushtaq S, Warner M. Activity of BAL30376 (monobactam BAL19764 + BAL29880 + clavulanate) versus Gram-negative bacteria with characterized resistance mechanisms. J Antimicrob Chemother 2010;65:2382-95
   PubMed Web of Science ®Google Scholar
• Livermore DM, Mushtaq S, Warner M, et al. Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase-Producing Enterobacteriaceae. Antimicrob Agents Chemother 2011;55:390-4
   PubMed Web of Science ®Google Scholar
• Mushtaq S, Warner M, Livermore DM. In vitro activity of ceftazidime+NXL104 against Pseudomonas aeruginosa and other non-fermenters. J Antimicrob Chemother 2010;65:2376-81
   PubMed Web of Science ®Google Scholar
• Mushtaq S, Warner M, Williams G, et al. Activity of chequerboard combinations of ceftaroline and NXL104 versus beta-lactamase-producing Enterobacteriaceae. J Antimicrob Chemother 2010;65:1428-32
   PubMed Web of Science ®Google Scholar
• Livermore DM, Warner M, Mushtaq S, et al. What remains against carbapenem-resistant Enterobacteriaceae? Evaluation of chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocillin and tigecycline. Int J Antimicrob Agents 2011;37:415-19
   PubMed Web of Science ®Google Scholar
• Livermore DM, Mushtaq S, Nguyen T, Warner M. Strategies to overcome extended-spectrum beta-lactamases (ESBLs) and AmpC beta-lactamases in shigellae. Int J Antimicrob Agents 2011;37:405-9
   PubMed Web of Science ®Google Scholar
• Giamarellou H. Multidrug-resistant Gram-negative bacteria: how to treat and for how long. Int J Antimicrob Agents 2010;36(Suppl 2):S50-4
   PubMed Web of Science ®Google Scholar
• Daikos GL, Markogiannakis A. Carbapenemase-producing Klebsiella pneumoniae: (when) might we still consider treating with carbapenems? Clin Microbiol Infect 2011;17:1135-41
   PubMed Web of Science ®Google Scholar
• Petrosillo N, Giannella M, Lewis R, Viale P. Treatment of carbapenem-resistant Klebsiella pneumoniae: the state of the art. Expert Rev Anti Infect Ther 2013;11:159-77
   PubMed Web of Science ®Google Scholar
• Freifeld A, Marchigiani D, Walsh T, et al. A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. N Engl J Med 1999;341:305-11
   PubMed Web of Science ®Google Scholar
• Kern WV, Cometta A, De Bock R, et al. Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med 1999;341:312-18
   PubMed Web of Science ®Google Scholar
• Cooper MR, Durand CR, Beaulac MT, Steinberg M. Single-agent, broad-spectrum fluoroquinolones for the outpatient treatment of low-risk febrile neutropenia. Ann Pharmacother 2011;45:1094-102
   PubMed Web of Science ®Google Scholar
• Kern WV, Marchetti O, Drgona L, et al. Oral antibiotics for fever in low-risk neutropenic patients with cancer: a double-blind, randomized, multicenter trial comparing single daily moxifloxacin with twice daily ciprofloxacin plus amoxicillin/clavulanic acid combination therapy–EORTC Infectious diseases Group Trial XV. J Clin Oncol 2013;31(9):1149-56
   PubMed Web of Science ®Google Scholar
• Chamilos G, Bamias A, Efstathiou E, et al. Outpatient treatment of low-risk neutropenic fever in cancer patients using oral moxifloxacin. Cancer 2005;103:2629-35
   PubMed Web of Science ®Google Scholar
• Sebban C, Dussart S, Fuhrmann C, et al. Oral moxifloxacin or intravenous ceftriaxone for the treatment of low-risk neutropenic fever in cancer patients suitable for early hospital discharge. Support Care Cancer 2008;16:1017-23
   PubMed Web of Science ®Google Scholar
• Rolston KV, Frisbee-Hume SE, Patel S, et al. Oral moxifloxacin for outpatient treatment of low-risk, febrile neutropenic patients. Support Care Cancer 2010;18:89-94
   PubMed Web of Science ®Google Scholar
• Shinohara A, Yoshiki Y, Masamoto Y, et al. Moxifloxacin is more effective in reducing chemotherapy-induced febrile neutropenia with hematological malignancies than tosufloxacin. Leuk Lymphoma 2013;54:794-8
   PubMed Web of Science ®Google Scholar
• Talcott JA, Yeap BY, Clark JA, et al. Safety of early discharge for low-risk patients with febrile neutropenia: a multicenter randomized controlled trial. J Clin Oncol 2011;29:3977-83
   PubMed Web of Science ®Google Scholar
• Brack E, Bodmer N, Simon A, et al. First-day step-down to oral outpatient treatment versus continued standard treatment in children with cancer and low-risk fever in neutropenia. A randomized controlled trial within the multicenter SPOG 2003 FN study. Pediatr Blood Cancer 2012;59:423-30
   PubMed Web of Science ®Google Scholar
• Pizzo PA, Robichaud KJ, Gill FA, et al. Duration of empiric antibiotic therapy in granulocytopenic patients with cancer. Am J Med 1979;67:194-200
   PubMed Web of Science ®Google Scholar
• Marchetti O, Cordonnier C, Calandra T. Empirical antifungal therapy in neutropaenic cancer patients with persistent fever. Eur J Cancer Suppl 2007;5:32-42
   Google Scholar
• Beck-Sagué CM, Jarvis WR. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. J Infect Dis 1993;167:1247-51
   PubMed Web of Science ®Google Scholar
• Bodey G, Bueltmann B, Duguid W, et al. Fungal infections in cancer patients: an international autopsy survey. Eur J Clin Microbiol Infect Dis 1992;11:99-109
   PubMed Web of Science ®Google Scholar
• Pizzo PA, Robichaud KJ, Gill FA, Witebsky FG. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med 1982;72:101-11
   PubMed Web of Science ®Google Scholar
• EORTC-IATCG. Empiric antifungal therapy in febrile granulocytopenic patients. Am J Med 1989;86:668-72
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 1999;340:764-71
   PubMed Web of Science ®Google Scholar
• de Pauw BE, Sable CA, Walsh TJ, et al. Impact of alternate definitions of fever resolution on the composite endpoint in clinical trials of empirical antifungal therapy for neutropenic patients with persistent fever: analysis of results from the Caspofungin Empirical Therapy Study. Transpl Infect Dis 2006;8:31-7
   PubMed Web of Science ®Google Scholar
• Bennett JE, Powers J, Walsh T, et al. Forum report: issues in clinical trials of empirical antifungal therapy in treating febrile neutropenic patients. Clin Infect Dis 2003;36:S117-22
   PubMed Web of Science ®Google Scholar
• Ullmann AJ, Heussel CP, Cornely OA. Voriconazole versus liposomal amphotericin B for empirical antifungal therapy. N Engl J Med 2002;346:1745-7; author reply 45-7
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Teppler H, Donowitz GR, et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004;351:1391-402
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Pappas P, Winston DJ, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002;346:225-34
   PubMed Web of Science ®Google Scholar
• Powers JH, Dixon CA, Goldberger MJ. Voriconazole versus liposomal amphotericin B in patients with neutropenia and persistent fever. N Engl J Med 2002;346:289-90
   PubMed Web of Science ®Google Scholar
• Johnson JR. Voriconazole versus liposomal amphotericin B for empirical antifungal therapy. N Engl J Med 2002;346:1745-7; author reply 45-7
   PubMedGoogle Scholar
• Offner F, Krcmery V, Boogaerts M, et al. Liposomal nystatin in patients with invasive aspergillosis refractory to or intolerant of amphotericin B. Antimicrob Agents Chemother 2004;48:4808-12
   PubMed Web of Science ®Google Scholar
• Boogaerts M, Winston DJ, Bow EJ, et al. Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial. Ann Intern Med 2001;135:412-22
   PubMed Web of Science ®Google Scholar
• Kubiak DW, Bryar JM, McDonnell AM, et al. Evaluation of caspofungin or micafungin as empiric antifungal therapy in adult patients with persistent febrile neutropenia: a retrospective, observational, sequential cohort analysis. Clin Ther 2010;32:637-48
   PubMed Web of Science ®Google Scholar
• Pappas PG, Rotstein CM, Betts RF, et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 2007;45:883-93
   PubMed Web of Science ®Google Scholar
• Kohno S, Izumikawa K, Yoshida M, et al. A double-blind comparative study of the safety and efficacy of caspofungin versus micafungin in the treatment of candidiasis and aspergillosis. Eur J Clin Microbiol Infect Dis 2013;32(3):387-97
   PubMed Web of Science ®Google Scholar
• Girmenia C, Micozzi A, Gentile G, et al. Clinically driven diagnostic antifungal approach in neutropenic patients: a Prospective Feasibility Study. J Clin Oncol 2010;28:667-74
   PubMed Web of Science ®Google Scholar
• Cordonnier C, Pautas C, Maury S, et al. Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial. Clin Infect Dis 2009;48:1042-51
   PubMed Web of Science ®Google Scholar
• Maertens J, Theunissen K, Verhoef G, et al. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis 2005;41:1242-50
   PubMed Web of Science ®Google Scholar
• Agrawal S, Hope W, Sinko J, Kibbler C. Optimizing management of invasive mould diseases. J Antimicrob Chemother 2011;66(Suppl 1):i45-53
   PubMedGoogle Scholar
• Pagano L, Caira M, Nosari A, et al. The use and efficacy of empirical versus pre-emptive therapy in the management of fungal infections: the HEMA e-Chart Project. Haematologica 2011;96:1366-70
   PubMed Web of Science ®Google Scholar
• De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008;46:1813-21
   PubMed Web of Science ®Google Scholar
• Aguilar-Guisado M, Martin-Pena A, Espigado I, et al. Universal antifungal therapy is not needed in persistent febrile neutropenia: a tailored diagnostic and therapeutic approach. Haematologica 2012;97:464-71
   PubMed Web of Science ®Google Scholar
• Aapro MS, Bohlius J, Cameron DA, et al. 2010 update of EORTC guidelines for the use of granulocyte colony-stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 2011;47:8-32
   PubMed Web of Science ®Google Scholar
• Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006;24:3187-205
   PubMed Web of Science ®Google Scholar
• Berghmans T, Paesmans M, Lafitte JJ, et al. Therapeutic use of granulocyte and granulocyte-macrophage colony-stimulating factors in febrile neutropenic cancer patients. A systematic review of the literature with meta-analysis. Support Care Cancer 2002;10:181-8
   PubMed Web of Science ®Google Scholar
• Mitchell PL, Morland B, Stevens MC, et al. Granulocyte colony-stimulating factor in established febrile neutropenia: a randomized study of pediatric patients. J Clin Oncol 1997;15:1163-70
   PubMed Web of Science ®Google Scholar
• Strauss RG. Role of granulocyte/neutrophil transfusions for haematology/oncology patients in the modern era. Br J Haematol 2012;158:299-303
   PubMed Web of Science ®Google Scholar
• Young JH. Epidemiology and management of infectious complications in contemporary management of chronic leukemias. Infect Dis Drug Targets 2011;11:3-10
   PubMedGoogle Scholar
• Viscoli C, Castagnola E. Prophylaxis and empirical therapy of infection in cancer patients. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and practice of Infectious diseases. Churchill-Livingstone Elsevier; Philadelphia: 2010. p. 3793-807
   Google Scholar
• Anonymous. Ceftazidime combined with a short or long course of amikacin for empirical therapy of gram-negative bacteremia in cancer patients with granulocytopenia. The EORTC International Antimicrobial Therapy Cooperative Group. N Engl J Med 1987;317:1692-8
   PubMedGoogle Scholar
• Livermore DM. Has the era of untreatable infections arrived? J Antimicrob Chemother 2009;64:i29-36
   PubMed Web of Science ®Google Scholar
• Viscoli C, Bruzzi P, Glauser M. An approach to the design and implementation of clinical trials of empirical antibiotic therapy in febrile and neutropenic cancer patients. Eur J Cancer 1995;31A:2013-22
   PubMed Web of Science ®Google Scholar
• Mullen CA. “Good enough” medicine: noninferiority clinical trials and the management of fever and neutropenia. Pediatr Blood Cancer 2012;59:415-16
   PubMed Web of Science ®Google Scholar